Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) CEO Dinesh V. Ph D. Patel sold 78,520 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $46.96, for a total value of $3,687,299.20. Following the sale, the chief executive officer now directly owns 435,208 shares in the company, valued at $20,437,367.68. This trade represents a 15.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Protagonist Therapeutics Price Performance
Protagonist Therapeutics stock opened at $43.80 on Friday. The firm has a market capitalization of $2.61 billion, a P/E ratio of 16.47 and a beta of 2.17. Protagonist Therapeutics, Inc. has a 1-year low of $17.70 and a 1-year high of $48.89. The company’s 50-day moving average is $45.15 and its 200 day moving average is $39.76.
Institutional Investors Weigh In On Protagonist Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Protagonist Therapeutics by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,130 shares of the company’s stock valued at $95,000 after acquiring an additional 379 shares during the period. GAMMA Investing LLC lifted its position in shares of Protagonist Therapeutics by 749.2% during the third quarter. GAMMA Investing LLC now owns 552 shares of the company’s stock worth $25,000 after purchasing an additional 487 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in shares of Protagonist Therapeutics during the third quarter valued at $43,000. CWM LLC grew its holdings in shares of Protagonist Therapeutics by 910.3% in the third quarter. CWM LLC now owns 1,273 shares of the company’s stock worth $57,000 after purchasing an additional 1,147 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in Protagonist Therapeutics in the 1st quarter worth about $35,000. 98.63% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
Read Our Latest Research Report on Protagonist Therapeutics
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.
Read More
- Five stocks we like better than Protagonist Therapeutics
- How to Use the MarketBeat Dividend Calculator
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- 3 Penny Stocks Ready to Break Out in 2025
- Want to Profit on the Downtrend? Downtrends, Explained.
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.